Comparison of endometrial regenerative cells and bone marrow stromal cells

Journal of Translational Medicine

David F Stroncek³  Thomas E Ichim¹  Vladimir Bogin¹  Sara Civini²  Jiaqiang Ren²  Marianna Sabatino²  Ping Jin²  Huan Wang² 

[1] MediStem Inc, San Diego, CA, USA;Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, MD, USA;Department of Transfusion Medicine, Cell Processing Section, 10 Center Drive-MSC-1288, Building 10, Room 3C720, Bethesda, MD, 20892-1288, USA

关键词: Regenerative medicine;    Mesenchymal stem cells;    Mesenchymal stromal cells;    Bone marrow stromal cells;    Endometrial regenerative cells;   

Others  :  1205896
DOI  :  10.1186/1479-5876-10-207

 received in 2012-07-31, accepted in 2012-09-19,  发布年份 2012

【 摘 要 】

Background

Endometrial regenerative cells (ERC) and bone marrow stromal cells (BMSC) are being used in clinical trials. While they have been reported to have similar characteristics, they have not been directly compared.

Methods

We compared micro RNA (miRNA) and gene expression profiles, soluble cytokine and growth factor levels and ability to inhibit ongoing mixed leukocyte reaction (MLR) of ERC and BMSC each derived from 6 healthy subjects.

Results

ERC and BMSC miRNA and gene expression profiles were similar, but not identical; more differences were noted in the expression of genes than in miRNAs. Genes overexpressed in ERCs were more likely to be in immune and inflammation pathways and those overexpressed in BMSCs were more likely to be in stem cell and cancer signaling pathways. In addition, the levels of IL-8 and ICAM-1 were greater in ERC supernatants while the levels of HGF, VEGF, IL-6, CXCL12, TGFB1 and TGFB2 were greater in BMSC supernatants. Additionally, ERC demonstrated greater inhibition of the proliferation of mixed leukocyte cultures.

Conclusions

These results suggest that the in vivo effects of ERC and BMSC may differ. Multiple properties of stromal cells are responsible for their in vivo effectiveness and ERC may be more effective for some of the clinical applications and BMSC for others. Studies in animal models or clinical trials will be required to more fully characterize the differences between ERC and BMSC.

【 授权许可】

   
2012 Wang et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

Figure 8.

【 参考文献 】

• [1]Friedenstein AJ, Chailakhjan RK, Lalykina KS: The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells. Cell Tissue Kinet 1970, 3:393-403.
• [2]Kolf CM, Cho E, Tuan RS: Mesenchymal stromal cells. biology of adult mesenchymal stem cells: regulation of niche, self-renewal and differentiation. Arthritis Res Ther 2007, 9:204. BioMed Central Full Text
• [3]Dominici M, Le BK, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop D, Horwitz E: Minimal criteria for defining multipotent mesenchymal stromal cells. the international society for cellular therapy position statement. Cytotherapy 2006, 8:315-317.
• [4]Prockop DJ: Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 1997, 276:71-74.
• [5]Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR: Multilineage potential of adult human mesenchymal stem cells. Science 1999, 284:143-147.
• [6]Kuznetsov SA, Mankani MH, Robey PG: In vivo formation of bone and haematopoietic territories by transplanted human bone marrow stromal cells generated in medium with and without osteogenic supplements. J Tissue Eng Regen Med 2011. [Epub ahead of print]
• [7]Zomorodian E, Baghaban EM: Mesenchymal stem cells as a potent cell source for bone regeneration. Stem Cells Int 2012, 2012:980353.
• [8]Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, Lanino E, Sundberg B, Bernardo ME, Remberger M, Dini G, Egeler RM, Bacigalupo A, Fibbe W, Ringden O: Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008, 371:1579-1586.
• [9]Le Blanc K, Rasmusson I, Sundberg B, Gotherstrom C, Hassan M, Uzunel M, Ringden O: Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004, 363:1439-1441.
• [10]Ringden O, Uzunel M, Rasmusson I, Remberger M, Sundberg B, Lonnies H, Marschall HU, Dlugosz A, Szakos A, Hassan Z, Omazic B, Aschan J, Barkholt L, Le BK: Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 2006, 81:1390-1397.
• [11]Gilchrist ES, Plevris JN: Bone marrow-derived stem cells in liver repair: 10 years down the line. Liver Transpl 2010, 16:118-129.
• [12]Zhou Y, Wang S, Yu Z, Hoyt RF Jr, Sachdev V, Vincent P, Arai AE, Kwak M, Burkett SS, Horvath KA: Direct injection of autologous mesenchymal stromal cells improves myocardial function. Biochem Biophys Res Commun 2009, 390:902-907.
• [13]Ciccocioppo R, Bernardo ME, Sgarella A, Maccario R, Avanzini MA, Ubezio C, Minelli A, Alvisi C, Vanoli A, Calliada F, Dionigi P, Perotti C, Locatelli F, Corazza GR: Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn's disease. Gut 2011, 60:788-798.
• [14]Meng X, Ichim TE, Zhong J, Rogers A, Yin Z, Jackson J, Wang H, Ge W, Bogin V, Chan KW, Thebaud B, Riordan NH: Endometrial regenerative cells: a novel stem cell population. J Transl Med 2007, 5:57. BioMed Central Full Text
• [15]Murphy MP, Wang H, Patel AN, Kambhampati S, Angle N, Chan K, Marleau AM, Pyszniak A, Carrier E, Ichim TE, Riordan NH: Allogeneic endometrial regenerative cells: an "Off the shelf solution" for critical limb ischemia? J Transl Med 2008, 6:45. BioMed Central Full Text
• [16]Han X, Meng X, Yin Z, Rogers A, Zhong J, Rillema P, Jackson JA, Ichim TE, Minev B, Carrier E, Patel AN, Murphy MP, Min WP, Riordan NH: Inhibition of intracranial glioma growth by endometrial regenerative cells. Cell Cycle 2009, 8:606-610.
• [17]Zhong Z, Patel AN, Ichim TE, Riordan NH, Wang H, Min WP, Woods EJ, Reid M, Mansilla E, Marin GH, Drago H, Murphy MP, Minev B: Feasibility investigation of allogeneic endometrial regenerative cells. J Transl Med 2009, 7:15. BioMed Central Full Text
• [18]Simon R, Lam A, Li MC, Ngan M, Menenzes S, Zhao Y: Analysis of gene expression data using BRB-ArrayTools. Cancer Inform 2007, 3:11-17.
• [19]Doorn J, Moll G, Le Blanc K, van Blitterswijk C, de Boer J: Therapeutic applications of mesenchymal stromal cells: paracrine effects and potential improvements. Tissue Eng Part B Rev 2012, 18:101-115.
• [20]Veitia RA: FOXL2 versus SOX9: a lifelong "battle of the sexes. Bioessays 2010, 32:375-380.
• [21]He YW, Li H, Zhang J, Hsu CL, Lin E, Zhang N, Guo J, Forbush KA, Bevan MJ: The extracellular matrix protein mindin is a pattern-recognition molecule for microbial pathogens. Nat Immunol 2004, 5:88-97.
• [22]Balber AE: Concise review: aldehyde dehydrogenase bright stem and progenitor cell populations from normal tissues: characteristics, activities, and emerging uses in regenerative medicine. Stem Cells 2011, 29:570-575.
• [23]Snyder SK, Wessner DH, Wessells JL, Waterhouse RM, Wahl LM, Zimmermann W, Dveksler GS: Pregnancy-specific glycoproteins function as immunomodulators by inducing secretion of IL-10, IL-6 and TGF-beta1 by human monocytes. Am J Reprod Immunol 2001, 45:205-216.
• [24]Fleetwood AJ, Cook AD, Hamilton JA: Functions of granulocyte-macrophage colony-stimulating factor. Crit Rev Immunol 2005, 25:405-428.
• [25]Fiedler U, Augustin HG: Angiopoietins: a link between angiogenesis and inflammation. Trends Immunol 2006, 27:552-558.
• [26]Hellberg C, Ostman A, Heldin CH: PDGF and vessel maturation. Recent Results Cancer Res 2010, 180:103-114.
• [27]Zheng L, Amano K, Iohara K, Ito M, Imabayashi K, Into T, Matsushita K, Nakamura H, Nakashima M: Matrix metalloproteinase-3 accelerates wound healing following dental pulp injury. Am J Pathol 2009, 175:1905-1914.
• [28]Vishnubalaji R, Al-Nbaheen M, Kadalmani B, Aldahmash A, Ramesh T: Comparative investigation of the differentiation capability of bone-marrow- and adipose-derived mesenchymal stem cells by qualitative and quantitative analysis. Cell Tissue Res 2012, 347:419-427.
• [29]Rebelatto CK, Aguiar AM, Moretao MP, Senegaglia AC, Hansen P, Barchiki F, Oliveira J, Martins J, Kuligovski C, Mansur F, Christofis A, Amaral VF, Brofman PS, Goldenberg S, Nakao LS, Correa A: Dissimilar differentiation of mesenchymal stem cells from bone marrow, umbilical cord blood, and adipose tissue. Exp Biol Med (Maywood) 2008, 233:901-913.
• [30]Bochev I, Elmadjian G, Kyurkchiev D, Tzvetanov L, Altankova I, Tivchev P, Kyurkchiev S: Mesenchymal stem cells from human bone marrow or adipose tissue differently modulate mitogen-stimulated B-cell immunoglobulin production in vitro. Cell Biol Int 2008, 32:384-393.
• [31]Kern S, Eichler H, Stoeve J, Kluter H, Bieback K: Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells 2006, 24:1294-1301.
• [32]Nora CC, Camassola M, Bellagamba B, Ikuta N, Christoff AP, Meirelles LD, Ayres R, Margis R, Nardi NB: Molecular analysis of the differentiation potential of murine mesenchymal stem cells from tissues of endodermal or mesodermal origin. Stem Cells Dev 2012, 21:1761-1768.
• [33]Peng L, Jia Z, Yin X, Zhang X, Liu Y, Chen P, Ma K, Zhou C: Comparative analysis of mesenchymal stem cells from bone marrow, cartilage, and adipose tissue. Stem Cells Dev 2008, 17:761-773.
• [34]Keyser KA, Beagles KE, Kiem HP: Comparison of mesenchymal stem cells from different tissues to suppress T-cell activation. Cell Transplant 2007, 16:555-562.
• [35]Haniffa MA, Collin MP, Buckley CD, Dazzi F: Mesenchymal stem cells: the fibroblasts' new clothes? Haematologica 2009, 94:258-263.
• [36]Lysy PA, Smets F, Sibille C, Najimi M, Sokal EM: Human skin fibroblasts: From mesodermal to hepatocyte-like differentiation. Hepatology 2007, 46:1574-1585.
• [37]Haniffa MA, Wang XN, Holtick U, Rae M, Isaacs JD, Dickinson AM, Hilkens CM, Collin MP: Adult human fibroblasts are potent immunoregulatory cells and functionally equivalent to mesenchymal stem cells. J Immunol 2007, 179:1595-1604.